Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Implantica AG
  6. Summary
    IMP A SDB   SE0014855029

IMPLANTICA AG

(IMP A SDB)
  Report
Delayed Nasdaq Stockholm  -  04:40 2022-08-15 am EDT
42.70 SEK   +1.30%
05/11Implantica AG Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
03/07Implantica Ag Announces Launch of Refluxstop™ in Uk
CI
02/21Implantica AG Announces Filing of Comprehensive eHealth Patent Applications for Its Platform Technology
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Stockholm
08/09/2022 08/10/2022 08/11/2022 08/12/2022 08/15/2022 Date
40.25(c) 39.6(c) 43.2(c) 42.15(c) 42.7 Last
3 393 40 360 16 850 9 879 366 Volume
+0.63% -1.61% +9.09% -2.43% +1.30% Change
More quotes
Estimated financial data (e)
Sales 2022 1,87 M 1,91 M 1,91 M
Net income 2022 -23,1 M -23,7 M -23,7 M
Net cash position 2022 103 M 105 M 105 M
P/E ratio 2022 -10,1x
Yield 2022 -
Sales 2023 13,4 M 13,8 M 13,8 M
Net income 2023 -57,1 M -58,6 M -58,6 M
Net cash position 2023 42,3 M 43,4 M 43,4 M
P/E ratio 2023 -4,10x
Yield 2023 -
Capitalization 1 140 M 1 169 M 1 169 M
EV / Sales 2022 556x
EV / Sales 2023 81,8x
Nbr of Employees 29
Free-Float 4,86%
More Financials
Company
Implantica AG is a medtech company. The Company was founded in 2015 and is located in Vaduz, Liechtenstein. It has operations within the implantable medical device and eHealth markets. The Company's lead product RefluxStop is a passive CE-marked implant for prevention of gastroesophageal reflux. 
Read more
More about the company
Ratings of Implantica AG
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about IMPLANTICA AG
05/11Implantica AG Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
03/07Implantica Ag Announces Launch of Refluxstop™ in Uk
CI
02/21Implantica AG Announces Filing of Comprehensive eHealth Patent Applications for Its Pla..
CI
02/18Implantica AG Reports Earnings Results for the Fourth Quarter Ended December 31, 2021
CI
02/18Implantica AG Reports Earnings Results for the Full Year Ended December 31, 2021
CI
02/01Implantica Appoints New COO
MT
02/01Implantica AG Appoints Paul Meadas as Chief Operating Officer
CI
2021Implantica Successfully Performs Cadaver Implantations of Pipeline Products and Several..
CI
2021Implantica AG Reports Earnings Results for the Third Quarter and Nine Months Ended Sept..
CI
2021Implantica Names New Chief Market Access, Strategy Officer
MT
2021Implantica AG Appoints Amit Kukreja in the Position of Chief Market Access & Strategy O..
CI
2021Implantica AG Announces Feedback from Its Third Pre-Submission Meeting with the U.S. Fo..
CI
2021Implantica Announces Initial UK Surgical Training for RefluxStop™
CI
2021Certain Class A Shares of Implantica AG are subject to a Lock-Up Agreement Ending on 17..
CI
2021Certain Class B Shares of Implantica AG are subject to a Lock-Up Agreement Ending on 17..
CI
More news
News in other languages on IMPLANTICA AG
05/11Implantica AG annonce ses résultats pour le premier trimestre clos le 31 mars 2022
03/07Implantica Ag annonce le lancement de Refluxstop㬱 ; au Royaume-Uni.
02/21Implantica AG annonce le dépôt de demandes de brevets complètes dans le domaine de la s..
02/18Implantica AG annonce ses résultats pour le quatrième trimestre clos le 31 décembre 202..
02/18Implantica AG annonce ses résultats pour l'exercice complet clos le 31 décembre 2021
More news
Chart IMPLANTICA AG
Duration : Period :
Implantica AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IMPLANTICA AG
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 4,03 €
Average target price 10,15 €
Spread / Average Target 152%
EPS Revisions
Managers and Directors
Peter Forsell Chief Executive Officer
Andreas Öhrnberg Chief Financial Officer
Liselott Kilaas Chairman
Paul Mead Chief Operating Officer
Johan Bojs Vice Chairman
Sector and Competitors
1st jan.Capi. (M$)
IMPLANTICA AG-35.15%1 169
SHOCKWAVE MEDICAL, INC.62.13%10 388
NOVOCURE LIMITED14.44%8 999
MASIMO CORPORATION-47.27%8 109
PENUMBRA, INC.-40.13%6 518
GETINGE AB-43.33%5 975